Latest for 22q11.2 Deletion Syndrome
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial sites3 new sites opened for ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric… (BillionToOne)ClinicalTrials.gov
- Who can joinWho can join changed for Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents… (Phase 2)ClinicalTrials.gov
More about 22q11.2 Deletion Syndrome
5-3 Mb microdeletion on chromosome 22q11.2, affecting approximately 50 genes. This is the most common recurrent microdeletion in humans, occurring in approximately 1 in 2,000-4,500 people. The deletion results from non-allelic homologous recombination between low copy repeats (LCRs) flanking the 22q11.2 region.
Keep reading about 22q11.2 Deletion Syndrome
Clinical manifestations are highly variable due to variable breakpoints and gene dosage effects, even among family members.
The 'CATCH-22' mnemonic describes cardinal features: Cardiac defects (occurring in ~75-80%, especially conotruncal abnormalities including tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch), Abnormal facies (dysmorphic features), Cleft palate or velopharyngeal insufficiency (occurring in ~30-40%), Thymic hypoplasia (causing variable immunodeficiency in ~75%), Hypocalcemia (from parathyroid hypoplasia in ~50%), and 22q11 deletion.
Additional features include learning disability and developmental delay (occurring in ~70%), speech delays, hearing loss, renal anomalies, and increased psychiatric manifestations particularly schizophrenia.
What are the symptoms of 22q11.2 Deletion Syndrome?
These are common symptoms of 22q11.2 Deletion Syndrome, and how strong they are varies from person to person.
- Cardiac defects (conotruncal abnormalities, especially Tetralogy of Fallot)
- Cleft palate and velopharyngeal insufficiency
- Immune deficiency from thymic hypoplasia
- Hypocalcemia and hypoparathyroidism
- Intellectual and developmental disability
- Learning problems and speech delays
Who gets 22q11.2 Deletion Syndrome?
22q11.2 deletion syndrome shows autosomal dominant inheritance; approximately 90% of cases represent de novo (new) mutations, while approximately 10% are inherited from an affected parent with variable expressivity.
The condition affects males and females equally. The deletion occurs across all ethnic groups and geographic populations without significant population predisposition or founder effects. Prognosis varies significantly based on the specific genes involved and the presence or severity of cardiac abnormalities, immunodeficiency, and psychiatric manifestations.
Early diagnosis (through prenatal diagnosis, newborn screening, or clinical recognition in infancy) enables preventive measures and early intervention. Recurrence risk for unaffected parents is <1%; for an affected parent, the recurrence risk is 50% per pregnancy (though expressivity is variable). Germline mosaicism has been reported rarely in phenotypically normal parents.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for 22q11.2 Deletion Syndrome
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted 22q11.2 Deletion Syndrome resources
Reputable organizations and medical references for learning more about 22q11.2 Deletion Syndrome, including disease registries, foundation resources, and clinical guidelines.